Cite
Shapiro GI, O'Mara E, Laskin OL, et al. Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2021;10(8):940-949doi: 10.1002/cpdd.904.
Shapiro, G. I., O'Mara, E., Laskin, O. L., Gao, L., Baird, J. D., Spiegel, R. J., Kaushik, D., Weetall, M., Colacino, J., O'Keefe, K., Branstrom, A., Goodwin, E., Infante, J., Bedard, P. L., & Kong, R. (2021). Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors. Clinical pharmacology in drug development, 10(8), 940-949. https://doi.org/10.1002/cpdd.904
Shapiro, Geoffrey I, et al. "Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors." Clinical pharmacology in drug development vol. 10,8 (2021): 940-949. doi: https://doi.org/10.1002/cpdd.904
Shapiro GI, O'Mara E, Laskin OL, Gao L, Baird JD, Spiegel RJ, Kaushik D, Weetall M, Colacino J, O'Keefe K, Branstrom A, Goodwin E, Infante J, Bedard PL, Kong R. Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2021 Aug;10(8):940-949. doi: 10.1002/cpdd.904. Epub 2021 Jan 13. PMID: 33440067.
Copy
Download .nbib